Background: The low-FODMAP diet is a frequently used treatment for irritable bowel
life (QOL) 4, 5 and is associated with increased healthcare utilization 6 and has significant economic consequences. 1, 7 Over 80% of IBS patients report food-related symptoms and this is independently associated with reduced QOL. demonstrate short-term (up to 6 weeks) global and individual symptom improvement in IBS and have been reviewed elsewhere. 19 The diet involves restriction of high-FODMAP foods for 4-6 weeks to achieve symptom improvement followed by systematic reintroduction to identify the tolerance threshold for individual FODMAPs, which enables long-term self-management of symptoms and increasing dietary variety.
The low-FODMAP diet is a complex intervention and should be implemented with counseling from a dietitian. [20] [21] [22] To date, research has reported on clinical and nutritional outcomes following shortterm FODMAP restriction. 10, 13 However, there are concerns regarding the nutritional adequacy of the diet and inadequate calcium intake following 4 weeks of FODMAP restriction. 13 Furthermore, there are concerns regarding long-term acceptability of the diet. 12, 18 Data on the long-term effectiveness, nutritional adequacy and acceptability of the low-FODMAP diet are scarce. For example, studies have reported symptoms retrospectively 12, 23 or symptoms and acceptability prospectively. 18, 24 However, there has been no evaluation of dietary intake or other aspects of the diet in relation to food-related QOL and effects on healthcare utilization in the long term.
The extensive elimination of foods and the likelihood that many patients that respond will require dietary modification in the long term, coupled with the increasing use of the low-FODMAP diet warrants a comprehensive evaluation of long-term outcomes. Therefore, the aims of this study were to assess the long-term impact of the low-FODMAP diet on clinical response, high-and low-FODMAP food frequency, nutritional adequacy, dietary acceptability, food-related QOL, and healthcare utilization in patients with IBS.
| MATERIALS AND METHODS

| Study design
This study was a prospective long-term follow-up postal questionnaire study. Consecutive patients diagnosed with IBS in accordance with the National Institute of Health and Care Excellence (NICE) (abdominal pain/discomfort, bloating or change in bowel habit for at least 6 months in the absence of organic disease) 21 were recruited from both secondary care (Guy's and St Thomas' NHS Foundation Trust, London, UK) and primary care (Somerset Partnership NHS Foundation Trust, Somerset, UK). All eligible patients had been counseled on the low-FODMAP diet by a specialist gastroenterology dietitian and had received two clinical appointments; the initial appointment for dietary education on FODMAP restriction (baseline) and the follow-up appointment at least 6 weeks later when they had been following the low-FODMAP diet (short-term follow-up) at which point they were educated on FODMAP reintroduction. The prospective long-term follow-up performed as part of this study (long-term follow-up) occurred at least 6 months and no more than 18 months after short-term follow-up. Thus, data were collected from three time points, the first two of which were part of routine clinical care where only symptom data were collected.
At baseline, patients had been instructed to restrict their intake of high-FODMAP foods for at least 6 weeks. Written guidance on suitable and unsuitable foods and appropriate low-FODMAP food products for the restriction phase of the diet was provided. At short-term follow-up, counseling on FODMAP reintroduction was provided. Patients were instructed to undertake 3-day FODMAP food challenges using increasing food portions to identify individual FODMAPs that triggered symptoms. This process enabled patients to reintroduce some high-FODMAP foods to their tolerance threshold. Both appointments were conducted as per normal clinical practice as described elsewhere.
14,15
Patients were ineligible for the prospective long-term follow-up study if they had failed to attend the short-term follow-up clinical appointment; had experienced an acute gastrointestinal episode in the 4 weeks prior to long-term follow-up; had been diagnosed with a co-existing gastrointestinal disease (eg, inflammatory bowel disease, celiac disease), an eating disorder or a significant psychiatric disorder since baseline; or were unable to give informed consent.
The study was carried out in accordance with the Declaration of
Helsinki and was approved by the East of Scotland Research and Ethics
Committee (REC reference: 13/ES/0158). Participation was voluntary and all data were confidential and were reported anonymously. All patients provided written informed consent at long-term follow-up.
At the prospective long-term follow-up patients were asked to report their current weight and height and whether their weight had changed during FODMAP restriction. Patients were also asked to rate their current knowledge of the low-FODMAP diet using a 5-point Likert scale
(extremely poor; below average; average; above average; excellent).
| Gastrointestinal symptoms and stool output
Data for symptoms and stool output were available for baseline,
short-term follow-up (from clinical records), and long-term follow-up
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• The findings support using the low-FODMAP diet for long-term IBS management.
(from prospective survey). Data from baseline and short-term followup clinical appointments were matched to the long-term follow-up data using a unique anonymized identifier. [29] [30] [31] Frequency data on the consumption of foods high and low in individual FODMAPs was assessed based on cutoffs. 32 Each food frequency questionnaire food item was categorized as high-or low-FODMAP and, if high, which FODMAP(s) they contained. Food items were also categorized into food groups and sub-groups to assess daily intakes. Low-FODMAP speciality foods were included within their respective food group, eg, low-FODMAP cereals and grains included gluten-free bread, and low-FODMAP milk included lactose-free cow's milk. Additionally, daily intakes of onion and garlic were assessed as they contribute a large amount of fructans to the diet. 33 The proportion of patients who consumed foods high in individual FODMAPs (fructans, galacto-oligosaccharides, lactose, fructose, sorbitol, and mannitol) at least once a week was assessed between groups.
Patients were asked to record their dietary adherence to long-term FODMAP restriction using a 4-point Likert scale: 'continued strict low-FODMAP diet', 'reintroduced high-FODMAP foods to tolerance', 'continued low-FODMAP diet 50% of the time', 'returned to habitual diet'.
The 'adapted FODMAP' group included the first three of these.
Acceptability of dietary restriction was assessed at long-term follow-up using a 14-item questionnaire adapted from the nutritionrelated QOL questionnaire. 34 Questions considered the impact and challenges of diet on eating environment, travel, meal enjoyment, cost, shopping, and cooking. Data were scored using a 5-point Likert scale
(strongly agree, agree, neutral, disagree, and strongly disagree).
The impact of the low-FODMAP diet on QOL was assessed at long-term follow-up using a seven-item questionnaire based on a generic validated food-related QOL tool (Satisfaction with Food-related Life). 35 Data were scored using a 5-point Likert scale (strongly agree, agree, neutral, disagree, and strongly disagree).
| Healthcare utilization and work absenteeism
At long-term follow-up patients were asked to record how often they visited their general practitioner or gastroenterologist for gastrointestinal symptoms during the previous 12 months, what IBS medication they were currently taking, if it had changed since being advised on the low-FODMAP diet, and whether they were absent from work due to their gastrointestinal symptoms in the same period.
| Statistical analysis
The primary outcome was global symptom relief at long-term followup compared with baseline. The sample size was calculated to detect a difference in the primary outcome assuming 60% of patients who had reported global symptom relief at short-term follow-up would continue to report it at long-term follow-up vs 10% of patients who had not reported global symptom relief at short-term follow-up would report it at long-term follow-up. A total of 80 completed questionnaires were required at 90% power for detecting a difference in the primary outcome at P=.05 significance level. From previous experience of postal invitation to a dietary intake study, it was anticipated that at least 20% of subjects invited would complete and return the questionnaires, 36 thus it was assumed that 380 patients would be invited to achieve the sample size requirement.
Returned questionnaires were excluded from analysis if more than 10% of questions had not been answered. Individual symptom responses assessed by the GSRS were collapsed into a dichotomous response to report the presence or absence of 'moderate or severe' symptoms as previously reported. 15 Stool frequency was reclassified into normal (once every 3 days to three times a day) or abnormal (less than once every 3 days or more than three times a day). Stool consistency was reclassified into normal (Bristol Stool Form types 3, 4, or 5) or abnormal (Bristol Stool Form types 1, 2, 6, or 7) as previously reported. 15 For dietary intake, dietary acceptability, foodrelated QOL, work absenteeism, and healthcare utilization comparisons, patients were collapsed into a dichotomous response set according to whether they returned to a habitual diet ('habitual') or continued to restrict high-FODMAP foods ('adapted FODMAP') at long-term follow-up. Categorical data for dietary acceptability and food-related QOL were collapsed into three group response sets to provide clinically meaningful interpretation and data distribution for analysis.
All data were analyzed using SPSS, version 22 (SPSS Inc, Chicago, IL, USA). Demographic and baseline symptoms were analyzed descriptively. Data are reported as mean±standard deviation (SD) with 95%
confidence intervals for continuous data and n (%) for categorical data, unless otherwise indicated. A Bonferroni correction was applied for multiple comparisons where required. Statistical significance was considered where P<.05.
Macronutrient and micronutrient intakes were assessed for adequacy in comparison to the UK recommendations. Food frequency intakes from the food frequency questionnaire were converted to daily intakes using previously published conversion factors. 37 Daily intakes were adjusted to account for the total number of foods reported as consumed by each subject.
| RESULTS
A total of 375 (n=309 secondary care, n=66 primary care) patients were eligible and invited to participate in the study. Of these, 232 did not respond to the invitation to participate, thus 143 were consented and recruited ( Figure 1 ). Thirty patients agreed to take part initially but did not return the questionnaire while seven withdrew stating lack of time or personal reasons, and three patients returned incomplete questionnaire and were excluded from analysis. Therefore, 103 patients were analyzed at long-term follow-up ( 
| Gastrointestinal symptoms and stool output
At baseline, 12 (12%) patients reported satisfactory symptom relief, which increased to 63 (61%) patients at short-term follow-up (FODMAP restriction) and to 59 (57%) patients at long-term followup ( Figure 2 ; P=.003). There were no significant differences for sat- and decreased by at least a third at long-term follow-up. There was a significant reduction in the proportion of patients reporting abnormal stool frequency (baseline 21%; short-term follow-up 7%; longterm follow-up 7% P<.001) and abnormal stool consistency (baseline 65%; short-term follow-up 43%; long-term follow-up 42% P=.001) (Cochran test).
| Dietary intake, acceptability, and food-related quality of life
At long-term follow-up, 84 (82%) patients continued to follow an 'adapted FODMAP' diet, while 19 (18%) returned to a 'habitual' diet.
There were no significant differences between groups at long-term follow-up for energy and nutrient intakes, except for folate and vitamin A which were both higher in the 'adapted FODMAP' group compared with the 'habitual' group ( Remained the same weight n (%) 48 (47) 30 (29) 18 (18) Gained weight n (%) 13 (12) 13 (12) 0 Knowledge and understanding of the low-FODMAP diet n (%) a Average n (%) 35 (35) 28 (27) 7 (7) 0.465 b Above average n (%) 55 (56) 38 (37) 17 (17) Excellent n (%) 9 (9) 5 (5) T A B L E 1 Demographics of irritable bowel syndrome patients at long-term follow-up Significantly fewer patients in the 'adapted FODMAP' group ate high fructan foods at least once a week (21% vs 30% P<.001) or foods containing high levels of free fructose at least once a week (17% vs 27% P<.001) compared with the 'habitual' group, and there were no differences between groups for foods containing high levels of lactose, galacto-oligosaccharides, sorbitol, or mannitol (Table 4 ).
There were no significant differences between groups for the majority of components of dietary acceptability ( P=.014). However, there were no significant differences for any of the components of food-related QOL between groups (Table 5 ).
| Healthcare utilization and resources
There were no significant differences for healthcare utilization be- 
| DISCUSSION
This is the first study to comprehensively report on the long-term implications of the low-FODMAP diet in patients with IBS 6-18 months following dietitian-led education. A majority of patients (82%) educated on the low-FODMAP diet continued with a personalized adaptation of the diet to self-manage their symptoms in the long term and 57% of F I G U R E 3 Proportion of patients reporting the presence of individual gastrointestinal symptoms at baseline, short-term follow-up and long-term follow-up (n=103) Baseline Shortterm follow-up Long-term follow-up P Significant differences between baseline and long-term follow-up all patients who received low-FODMAP education continued to report long-term satisfactory relief. Nutritional requirements were met by the majority of patients and long-term nutritional adequacy was not compromised when compared with the 'habitual' diet group. Overall, patients found the 'adapted FODMAP' diet acceptable and it did not negatively affect their food-related QOL, healthcare utilization, and work absenteeism more than patients who had returned to a 'habitual' diet. found that at 14 months follow-up 77% of patients were adherent to the diet with 76% reporting significant improvement in abdominal symptoms. 12 Prospective data on adherence are similar to our current study; 76% of participants were adherent to the low-FODMAP diet at a mean 16 months follow-up, but satisfaction with symptom response was slightly greater at 72% of patients than that observed herein.
18
In a randomized non-blinded trial which compared the low-FODMAP diet with hypnotherapy, 82% of patients who had responded to the diet maintained satisfactory relief of symptoms at 6 months, equating to 58% of all patients who had received dietary advice. 24 Cumulatively, long-term adherence to the low-FODMAP diet is not only maintained in the majority of patients but is also associated with significant T A B L E 3 Dietary intake of high-and low-FODMAP food groups for IBS patients at long-term follow-up Independent t test.
a Foods described as gluten-free in the food frequency questionnaire were included in this group or sub-group. Foods described as lactose-free in the food frequency questionnaire were included in this group or sub-group. c Includes honey, sugar-free chewing gum (high in polyols).
improvement in symptom response. The variation observed between studies may be explained, at least in part, by differences in study design such as the high level of response bias in retrospective studies.
Individual symptom severity reduced at both short-and longterm follow-up. Significant reductions in abdominal pain, bloating, flatulence, incomplete evacuation, and lethargy were reported, with pain, bloating, and flatulence decreasing by more than one-third in the long term. These findings are consistent with existing short 10, 13, 14, 16, 17 and long-term literature 18, 23, 24, 38 as well as a recent systemic review and meta-analysis. 39 The study cohort had a low reporting of abnormal stool frequency at baseline which is not uncommon in IBS due to its relapsing and remitting nature. The enduring symptom alleviation associated with the diet is a remarkable advantage of FODMAP therapy particularly compared to pharmaceutical management where (5) 2 (10) 63 (76) 9 (11) 11 (13) .698
I use high street/online speciality shops (eg, health food shops) to buy food for my current diet
7 (41) 6 (35) 4 (24) 28 (33) 14 (17) 42 (50 (17) .067
The cost of my current diet is more expensive 8 (42) 9 (47) 2 (11) 72 (86) 11 (13) 1 (1) <.001
Does eating out at restaurants make it more difficult for you to follow your current diet?
11 (58) 1 (5) 7 (37) 66 (79) 8 (10) 10 (12) .030
Does eating out at friends/families make it more difficult for you to follow your current diet?
9 (48) 3 (16) 7 (37) 61 (72) 15 (18) 8 (9) .009
Does travel (overseas/UK) make it more difficult for you to follow your current diet? a 9 (48) 3 (16) 7 (37) 63 (76) 11 (13) 9 (11) .014
Overall, I find my current diet tasty and enjoyable 14 (74) 3 (16) 2 (10) 53 (63) 15 (18) 16 (19) . 622 I can incorporate my current diet easily into my life a 10 (55) 4 (22) 4 (22) 47 (56) 20 (24) 17 (20) .978
My current dietary needs have created stress with my family/ friends a 5 (28) 3 (17) 10 (55) 20 (24) 16 (19) 48 (57) .929
Food-related quality of life (29) 27 (32) 32 (38) .329
With regard to food, the conditions of my life are excellent 8 (42) 7 (37) 4 (21) 27 (33) 28 (34) 28 (34) .535
Food and meals give me satisfaction in daily life 10 (53) 7 (37) 2 (10) 47 (56) 20 (24) 17 (20 symptom relief is limited at best. 40 Dietary management of IBS is associated with increased feelings of self-control and empowerment 41 and may foster greater long-term self-management.
The lack of robust long-term nutrient data and the identification of at risk nutrients in short-term studies 14 have raised questions regarding the nutritional adequacy, and therefore suitability, of the diet for long-term management. A key finding herein is that an 'adapted FODMAP' diet maintained for 6-18 months achieved nutritional adequacy and any deficits in energy or nutrient intakes were similar to those expected in the background population.
42
In short-term studies of the low-FODMAP diet, total carbohydrate intakes of 200 g/d have been observed following FODMAP restriction; 9,13 however, the current study reports a 20% higher total carbohydrate intake. A gluten-free diet for management of celiac disease is associated with a similar trend that is a reduction in carbohydrate intake observed in patients new to the diet followed by an increase in experienced users. 43, 44 There was no reduction in long-term dietary fiber intake. Data on dietary fiber intakes in short-term studies are inconsistent. Two studies report similar levels to baseline, 13, 45 while another shows a significant reduction in intake following FODMAP restriction. 9 A reduction in dietary fiber intake during FODMAP restriction is plausible given the stringent reduction of some staple cereals and legumes. However, in the long term, we observed a greater proportion of patients meeting the dietary fiber nutrient requirements on an 'adapted FODMAP' diet having reintroduced foods high in FODMAPs to individual tolerance than for those patients who had returned to a 'habitual' diet. This may be due to increased familiarity with the diet and greater understanding of low-FODMAP, high-fiber food choices.
Previous research suggests that FODMAP restriction leads to lower calcium intakes in the short term. 13 In the current study, mean calcium intakes were adequate and there was no difference in the proportion of patients that achieved their calcium requirement on an 'adapted FODMAP' diet compared with a 'habitual' diet. This may be due to a significant increase in lactose-free milk consumption (including calcium-fortified plant-based milks) in the 'adapted FODMAP' group such that calcium levels were maintained.
This is the first study to evaluate the intake of foods and food groups in patients following a low-FODMAP diet. Patients who continued to follow an 'adapted FODMAP' diet had a lower intake of garlic, onion, ready-meals, some high fructan cereal-based foods (eg, pasta), high-FODMAP sugars (eg, honey), and high-FODMAP miscellaneous and processed foods compared with the 'habitual' diet. Cereal products including pasta, wheat bran, and breakfast cereals have previously been identified as symptomatic triggers and the reduction of these is unsurprising. 46 A reduced intake of high-fat foods and miscellaneous and processed high-FODMAP foods for the 'adapted FODMAP' group signifies a move toward less high-fat, energy-dense food options and may, in part, explain the reported weight loss observed in over 40%
of those on an 'adapted FODMAP' diet. Previously, patients with IBS report greater induction of symptoms with fatty foods compared to controls 47 and those with IBS show hypersensitivity to lipid infusions compared to healthy individuals. 48 A reduction in bodyweight has been observed in individuals randomized to a low-FODMAP compared with 'habitual' diet 13 and a reduction in energy intake in another study. 9 Despite energy intake not being measured at baseline in the current study, 42% of patients reported weight reduction at long-term follow-up, this may be due to adopting a healthier eating pattern as described above. Weight and weight loss was self-reported and should be interpreted with caution.
50
To the best of our knowledge, this is the first study to investigate the long-term acceptability of the low-FODMAP diet. We report the diet causes disruption for eating out and with family/friends.
Consistent with a recent retrospective study, the diet was associated with increased cost. 23 All of these issues can be addressed during dietetic consultation. 14, 15 The low-FODMAP diet does not negatively affect food-related QOL nor does it adversely affect enjoyment of meals, cooking, shopping and integration into current lifestyles compared with patients who consume their 'habitual' diet. Given the large proportion of individuals affected by IBS and the known reduction in their QOL 4 alongside dissatisfaction with current treatments by at least 60% of patients, 51 these findings are of importance. They demonstrate that the diet is not only an effective treatment but it is also acceptable with improved QOL for this chronic disorder and patients with inflammatory bowel disease.
17,23,52
The economic impact of IBS is notable. 1, 53, 54 Recent data suggest that IBS accounts for in excess of £80 million in prescription costs alone and IBS patients are significant users of healthcare accounting for 7.5% of total outpatient visits across specialities. 7 The current findings indicate that healthcare usage and medication use is similar among those on an 'adapted FODMAP' diet and a 'habitual' diet; however, the expenditure appears to be slightly lower than that reported for UK patients with IBS. 1 Further work is required to assess healthcare usage of patients who do and do not receive low-FODMAP education.
There are several limitations of this study. Firstly, only 27% of the original sample invited to take part completed the study which is lower than other similar postal questionnaire studies.
18,55
While we acknowledge that it is possible we may have sampled a biased population of patients who had responded to the low-FODMAP diet, global symptom data from the baseline and short-term follow-up were similar for those who did and did not reply to the initial invite as reported previously. 18 Over 80% of subjects were recruited from an urban setting although most did not reply or had moved. Half of subjects invited from a rural area were recruited to the study. The higher response rate among these participants may possibly reflect the less transient nature of rural communities. In addition, the rural population was significantly older and included a smaller proportion of males than the urban population perhaps due to greater work opportunities for the younger population and for males in the urban area compared to elsewhere as reported from national data. 56 Secondly, the study design was a prospective questionnaire-based study that was uncontrolled and unblinded, thus increasing the risk of bias. Finally, given the lack of a disease activity biomarker in IBS, symptom evaluation was subjective and we acknowledge the limitations associated with subjective measures. 22, 57 Dietary intake was assessed by a food frequency questionnaire which has been validated to assess FODMAP intake; however, not in a UK population.
As with all food frequency questionnaires this approach can underestimate or overestimate intake of certain foods.
58
In summary, we report that the low-FODMAP diet is an effective long-term strategy for the management of IBS addressing an area which has, to date, been largely unexplored.
59-61
| CONCLUSION
This study prospectively evaluated the long-term impact of the low-FODMAP diet on symptom response, dietary intake, patient acceptability, and healthcare utilization in a large cohort of patients with IBS.
Patients report that the diet is clinically effective with 57% reporting long-term satisfactory symptom relief. Individuals who have received comprehensive education on the low-FODMAP diet have completed short-term FODMAP restriction followed by FODMAP reintroduction to individual tolerance. A low-FODMAP diet can be nutritionally adequate up to 18 months after initial education and patients find that the diet is acceptable and does not adversely impact on food-related QOL.
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